GLI1 and cancer: Targeting oncogenic HH/GLI activity in CSC alone or in combination with, for instance, chemo-, radio- or immune–therapeutic strategies is, therefore, a promising approach to improve the overall survival of many cancer patients by reducing cancer growth, metastatic spread, resistance development and relapses.